Otsuka Holdings (4578) FY2025 FY Earnings Report

Quick View

Executive Summary

This was a strong earnings period in which operating income growth significantly outpaced revenue growth, primarily due to higher earnings in the Healthcare-related Business and the reduction in the large impairment loss recorded in the previous fiscal year. Revenue increased +6.0% year on year to ¥2,468.89B, Operating Income increased +48.2% to ¥479.38B, Profit Before Tax increased +39.4% to ¥468.04B, and profit attributable to owners of the parent increased +5.8% to ¥363.15B (total Net Income increased +5.5% to ¥366.22B). The increase in Operating Income includes a comparative factor from the reduction in impairment losses from ¥126.04B in the previous fiscal year to ¥26.43B, a decrease of ¥99.61B; this must be evaluated together with the underlying improvement in business earnings power.

Factors Affecting Results

【Revenue】Revenue increased +6.0% year on year to ¥2,468.89B, with the core Healthcare-related Business (accounting for 70.6% of revenue) increasing revenue by +7.1% and driving the overall result. The Nutraceutical-related Business increased +3.7%, the Consumer-related Business increased +2.5%, and Other Businesses increased +2.1%; all recorded more moderate growth than the Healthcare-related Business.

【Profit and Loss】Operating Income increased +48.2% to ¥479.38B, and the Operating Income Margin expanded by 5.5pt from 13.9% in the previous year to 19.4%. The primary factors were the +56.2% increase in Operating Income from the Healthcare-related Business to ¥445.30B and the temporary impact of the ¥99.61B reduction in impairment losses. R&D expenses increased +12.3% while maintaining 14.3% of revenue, whereas SG&A expense growth of +4.8% was below the revenue growth rate, with operating leverage also contributing. The conversion rate from Profit Before Tax to profit attributable to owners of the parent was approximately 77.6%. Although the increase in financial expenses (+207.5%, ¥27.03B) was a downward factor, its impact was limited. Overall, this was a period of revenue and profit growth, characterized by profit growth significantly exceeding revenue growth, particularly in Operating Income.

Segment Analysis

The Healthcare-related Business generated revenue of ¥1,744.23B (70.6% of total, YoY +7.1%) and Operating Income of ¥445.30B (YoY +56.2%), with a margin of 25.5%, making it the core contributor to consolidated earnings. The Nutraceutical-related Business generated revenue of ¥577.62B (23.4% of total, YoY +3.7%), while Operating Income declined to ¥57.72B (YoY -3.4%), and its margin decreased from 10.7% in the previous year to 10.0%. Although the Consumer-related Business was small, with revenue of ¥34.61B, it achieved an extremely high margin of 72.7%, and Operating Income increased +9.4% to ¥25.15B. Other Businesses generated revenue of ¥112.43B and Operating Income of ¥7.98B (YoY +6.1%). The increase in consolidated Operating Income is highly dependent on the Healthcare-related Business, while the decline in profitability of the Nutraceutical-related Business should be monitored as a future diversification risk.

Key Financial Metrics

【Profitability】The Operating Income Margin was 19.4%, expanding by 5.5pt from 13.9% in the previous year, while the gross margin remained high at 71.7%. The Net Income Margin, based on profit attributable to owners of the parent, was 14.7%, broadly unchanged from 14.8% in the previous year. ROE was 12.6%, slightly down from 13.4% in the previous year. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥403.58B, equivalent to 1.11 times profit attributable to owners of the parent of ¥363.15B, indicating solid cash backing for earnings. Meanwhile, OCF/EBITDA was only 0.68 times, based on EBITDA of approximately ¥595.54B, calculated by adding depreciation and amortization of ¥116.17B; the increase in inventories (+25.5%) constrained cash generation. 【Investment Efficiency】Capital expenditures were ¥292.29B, reaching 2.52 times depreciation and amortization, indicating that the Company is in an investment phase. Free Cash Flow (OCF + Investing CF) was secured at ¥241.99B. 【Financial Soundness】The Equity Ratio was 72.3%, slightly down from 73.1% in the previous year but still at a high level. Total interest-bearing debt remained limited at approximately ¥130.75B, and the interest coverage ratio, calculated against financial expenses of ¥27.03B and EBIT of ¥479.38B, was approximately 17.7 times, indicating strong financial resilience.

Cash Flow Analysis

Operating Cash Flow was ¥403.58B, increasing +13.8% year on year. Improvement in profit on a subtotal basis, primarily due to higher Profit Before Tax and lower impairment losses, contributed positively, while a ¥53.47B cash outflow from inventories and cash outflows resulting from increases in trade receivables and other items were negative factors. Investing Cash Flow represented an outflow of ¥161.59B, primarily comprising capital expenditures of ¥292.29B and acquisitions of subsidiaries of ¥87.28B, indicating that the Company continues to actively pursue growth investment. Financing Cash Flow represented an outflow of ¥137.34B, mainly consisting of dividend payments of ¥70.98B and purchases of treasury shares of ¥70.10B. Free Cash Flow was positive at ¥241.99B, a level that broadly enables both shareholder returns and growth investments to be funded within the range of OCF. Cash and cash equivalents accumulated to ¥534.64B at period-end, increasing +25.4% from the end of the previous fiscal year.

Earnings Quality

Of the current-period Operating Income of ¥479.38B, the reduction in impairment losses from ¥126.04B in the previous fiscal year to ¥26.43B, a decrease of ¥99.61B, was a temporary comparative uplift and must be distinguished from a permanent improvement in business earnings power. Other income increased +174.5% year on year to ¥63.24B, but accounted for only 2.6% of revenue, indicating no excessive dependence on non-operating factors. Equity in earnings of affiliates accounted for using the equity method was ¥33.70B, broadly unchanged year on year, and functioned as a stable complementary factor equivalent to approximately 7.0% of Operating Income. Since OCF exceeded profit attributable to owners of the parent and accruals—the gap between accrual-based earnings and cash flows—did not expand excessively, earnings quality was generally sound. However, the increase in inventories is placing pressure on working capital, making inventory valuation and turnover efficiency in the next fiscal year and beyond key points to monitor in assessing earnings quality.

Earnings Forecasts and Guidance

The forecast for the next fiscal year is Revenue of ¥2,520.0B (+2.1% compared with the current fiscal year), Operating Income of ¥360.0B (-24.9%), Net Income of ¥269.0B (-27.0%), and forecast EPS of ¥504.94. The high profit level in the current fiscal year includes the temporary uplift from the reduction in impairment losses, and the forecast for the next fiscal year appears to reflect normalization after that effect. While moderate revenue growth is expected, a substantial decline in profit is forecast, indicating a scenario in which margins normalize despite revenue growth.

Shareholder Returns

The annual dividend was ¥140 per share (¥70 interim and ¥70 year-end), representing a substantial increase of +¥80 from ¥60 in the previous year. The Payout Ratio, based on profit attributable to owners of the parent, was 20.4%, rising from 18.9% in the previous year but remaining low. Treasury share purchases amounted to ¥70.10B, and together with dividend payments of ¥70.98B, total shareholder returns amounted to ¥141.07B. The Total Return Ratio relative to current-period Net Income was approximately 38.8%. Free Cash Flow of ¥241.99B exceeded total shareholder returns, indicating ample capacity to fund returns. The forecast dividend for the next fiscal year is also maintained at ¥140, resulting in a forecast Payout Ratio of approximately 27.7% based on forecast EPS of ¥504.94.

Risk Factors

1. Concentration of earnings in the Healthcare-related Business: The Healthcare-related Business accounts for 70.6% of revenue and the majority of consolidated Operating Income. Changes in drug price revisions, patents, and product life cycles in this business directly affect consolidated results.

2. Inventory growth and deterioration in working capital: Inventories increased +25.5% year on year, significantly exceeding the revenue growth rate of +6.0%. OCF/EBITDA remained at only 0.68 times, and inventory turnover and valuation risks are constraining cash generation capacity.

3. Sustainability of current-period profit growth: The increase in Operating Income includes the comparative factor of a ¥99.61B reduction in impairment losses, while the forecast for the next fiscal year anticipates declines of -24.9% in Operating Income and -27.0% in Net Income. The high margin level achieved in the current fiscal year is likely to normalize.

Industry Benchmark (For Reference; Company Analysis)

Key Takeaways from the Results

1. The Operating Income Margin expanded by 5.5pt to 19.4%, and together with the gross margin of 71.7%, demonstrates the high profitability of the business. However, it should be noted that part of this improvement reflects the temporary impact of the reversal of the large impairment loss recorded in the previous fiscal year.

2. Inventories are increasing at a pace exceeding revenue growth, making working capital efficiency and inventory valuation risk key factors that will determine future cash generation capacity.

3. With an Equity Ratio of 72.3% and interest coverage of approximately 17.7 times, financial capacity is substantial. The dividend was increased significantly by +¥80 year on year, leaving room to balance shareholder returns with growth investment.

Theoretical Share Price (Reference Value)

Sensitivity: ¥5,705–¥6,046 at Cost of Equity ±1%; ¥5,869–¥5,877 at ω±0.1.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this does not constitute a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---